Cite
HARVARD Citation
Sabetta, G. et al. (n.d.). 2022-RA-1274-ESGO Preliminary data about correlation between CA125 increase and recist progression in patients with relapsed ovarian cancer treated with maintenance PARP inhibitors or bevacizumab after response to platinum based chemotherapy. International journal of gynecological cancer. pp. A315-A316. [Online].